Encorafenib Plus Binimetinib Improves Long-Term PFS, OS in BRAF V600-Mutant Melanoma
Source: Cancer Therapy Advisor, August 2022
Encorafenib plus binimetinib can provide long-term benefits in patients with BRAF V600-mutant melanoma, according to research published in the Journal of Clinical Oncology.
A 5-year update from the COLUMBUS trial showed longer progression-free survival (PFS) and overall survival (OS) for patients who received encorafenib plus binimetinib, compared with those who received vemurafenib.
The combination also improved PFS when compared with encorafenib alone, but OS outcomes were similar between the combination and encorafenib monotherapy arms.